Drug Comparison

PillID

Pill Identifier Drug Encyclopedia Drug Classes Interactions Blog 🌙

Eliquis vs Xarelto: Key Differences

Eliquis (apixaban) and Xarelto (rivaroxaban) are both direct oral anticoagulants (DOACs) that work by inhibiting Factor Xa in the coagulation cascade. They have largely replaced warfarin for many indications due to their predictable pharmacokinetics, fewer dietary interactions, and no requirement for routine INR monitoring. Despite sharing a drug class and similar indications, they differ in half-life, dosing frequency, absorption requirements, and emerging evidence around bleeding outcomes.

Quick Comparison

Feature	Eliquis (Apixaban)	Xarelto (Rivaroxaban)
Drug Class	Direct Factor Xa Inhibitor	Direct Factor Xa Inhibitor
Brand Names	Eliquis	Xarelto
Half-Life	~12 hours	5–9 hours (young adults); 11–13 hours (elderly)
DEA Schedule	None	None
Pregnancy	Category B	Category C
Best For	AFib stroke prevention, DVT/PE treatment; twice-daily dosing provides steady anticoagulation	AFib stroke prevention, DVT/PE, postoperative prophylaxis; once-daily convenience for most indications

How They're Similar

Both apixaban and rivaroxaban directly and reversibly inhibit Factor Xa — a critical enzyme in the common pathway of coagulation — without requiring a cofactor such as antithrombin (unlike heparin) or depending on the Vitamin K pathway (unlike warfarin). This direct mechanism produces rapid anticoagulation after the first dose and does not require bridging therapy in most situations.

Neither drug requires routine coagulation monitoring (no INR checks), and both have far fewer dietary restrictions than warfarin. Both are approved for stroke prevention in non-valvular atrial fibrillation, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and reduction of recurrence risk after DVT/PE. Both are reversed by andexanet alfa (Andexxa), and both carry a black box warning regarding premature discontinuation in atrial fibrillation patients, which increases stroke risk.

Key Differences

Dosing Frequency and Adherence

Rivaroxaban offers once-daily dosing for most of its indications (AFib stroke prevention and secondary DVT/PE prevention), which many patients find convenient. Apixaban is administered twice daily for all its indications. While twice-daily dosing can be a burden for some patients, it also provides more consistent plasma levels throughout the day with fewer peak-to-trough fluctuations, which may contribute to more stable anticoagulation. Adherence data are mixed — for some patients twice daily is a barrier, while for others the reminders are an advantage.

Food Requirement

Rivaroxaban has a notable absorption quirk: the higher-strength tablets used for AFib and DVT/PE must be taken with the evening meal to achieve adequate bioavailability. Failing to take it with food can reduce absorption significantly. Apixaban does not have a food requirement and can be taken with or without food at any time of day, offering greater flexibility.

Bleeding Risk

Both carry inherent bleeding risks as anticoagulants. Indirect comparisons and some real-world database studies suggest apixaban may be associated with a lower risk of major bleeding — particularly gastrointestinal bleeding — compared to rivaroxaban. The landmark ARISTOTLE trial (apixaban vs. warfarin in AFib) showed apixaban superior to warfarin for both stroke prevention and major bleeding. The ROCKET-AF trial (rivaroxaban vs. warfarin) showed non-inferiority. Direct head-to-head RCT data comparing the two agents are limited; most comparative evidence is from observational studies.

Renal Considerations

Both are contraindicated in severe renal impairment (creatinine clearance below threshold for each drug). Rivaroxaban has greater renal elimination (about 33% unchanged in urine) and may need to be avoided or dose-adjusted at lower eGFR thresholds than apixaban. Apixaban is often considered the preferred DOAC in patients with significant chronic kidney disease who still meet criteria for anticoagulation.

Eliquis (Apixaban): Strengths & Weaknesses

Strengths

• May have lower GI bleeding risk compared to rivaroxaban based on observational data
• No food requirement for absorption
• Preferred DOAC in advanced CKD patients who still qualify for anticoagulation
• ARISTOTLE trial demonstrated superiority over warfarin in stroke prevention and major bleeding in AFib
• Pregnancy Category B (vs. Category C for rivaroxaban)

Weaknesses

• Twice-daily dosing — potential adherence challenge
• Higher cost; limited generic availability in some markets
• Missed doses can lead to gaps in anticoagulation due to shorter effective coverage window

Xarelto (Rivaroxaban): Strengths & Weaknesses

Strengths

• Once-daily dosing for most indications — simpler regimen for many patients
• FDA-approved for postoperative thromboprophylaxis (hip and knee replacement)
• Approved for cardiovascular risk reduction in stable CAD/PAD (with aspirin)
• Robust outcome trial data across multiple indications

Weaknesses

• Must be taken with evening meal for adequate absorption (major tablets)
• Possibly higher GI bleeding risk than apixaban in observational studies
• More renal elimination — greater concern in CKD patients
• Pregnancy Category C

Which Is Right for You?

The choice between apixaban and rivaroxaban often comes down to patient-specific factors: dosing preference (once vs. twice daily), history of GI bleeding, renal function, and cost or insurance coverage. For patients with advanced kidney disease or a history of GI bleeding, apixaban is often favored. For patients who strongly prefer once-daily dosing and who can reliably take the medication with their evening meal, rivaroxaban is a reasonable choice.

Frequently Asked Questions